Company

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor
HiDiamond BiotechnologyNerviano Medical Sciences

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor

Nerviano Medical Sciences S.r.l. (NMS), an Italy-based research and development company, and HiDiamond Biotechnology Co., Ltd. announced a collaboration and license agreement for NMS‑173, a highly potent, second-generation dual inhibitor…

OBiO Technology and Renyuan Biotechnology Forge Deep Strategic Collaboration – Advancing EPC Cell Therapy from Preclinical CMC to IND Filing

OBiO Technology and Renyuan Biotechnology Forge Deep Strategic Collaboration – Advancing EPC Cell Therapy from Preclinical CMC to IND Filing

Anke Biotechnology Signs Strategic AI Collaboration with DP Technology – Partnering on Intelligent Design of ADC Payload Molecules

Anke Biotechnology Signs Strategic AI Collaboration with DP Technology – Partnering on Intelligent Design of ADC Payload Molecules

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
CancerIPO

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Clinical trial approval / initiationKanghua Biological Products

Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

AbbVie's VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment
AbbVieNYSE: ABBV

AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment

SHA: 603392Vaccine

Beijing Wantai’s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China

Show More